Cargando…
P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England
Autores principales: | Jones, David, Shakir, Rebecca, Candio, Paolo, Ramroth, Johanna, Wolstenholme, Jane, Gray, Alastair, Cutter, David, Ntentas, Georgios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621529/ http://dx.doi.org/10.1097/01.HS9.0000890948.68238.c6 |
Ejemplares similares
-
Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry
por: Jones, David A., et al.
Publicado: (2022) -
P077: Predicting radiotherapy dose to the heart and the risk of radiation-related cardiac toxicity for Hodgkin lymphoma patients, using pre-chemotherapy PET-CT scans
por: Shakir, Rebecca, et al.
Publicado: (2022) -
P091: Early analysis of the PRO-Hodgkin study: Clinical investigation of pencil beam scanning proton treatment in Hodgkin lymphoma patients
por: Goldkuhl, Christina, et al.
Publicado: (2022) -
P094: Long-term outcomes of bulky classic Hodgkin lymphoma managed with a PET-adapted approach demonstrate excellent outcomes in PET-negative cases
por: Kim, Jowon Laura, et al.
Publicado: (2022) -
P096: Polymorphisms in SETD7 may predispose the risk of developing late cardiac side effects after radiotherapy including the mediastinum in Hodgkin’ s lymphoma.
por: Linderoth, Johan, et al.
Publicado: (2022)